Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Axsome Therapeutics (AXSM) PT Raised to $130 at RBC Capital
June 5, 2024 6:10 AM EDTRBC Capital analyst Leonid Timashev raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $130.00 (from $127.00) while maintaining a Outperform rating.
The analyst comments "We believe the strength of Auvelity's IP is a major point of sensitivity for AXSM shares given the drug's... More
